Chemistry: molecular biology and microbiology – Animal cell – per se ; composition thereof; process of... – Primate cell – per se
Reexamination Certificate
2006-05-23
2006-05-23
Ketter, James (Department: 1636)
Chemistry: molecular biology and microbiology
Animal cell, per se ; composition thereof; process of...
Primate cell, per se
C514S04400A, C424S450000
Reexamination Certificate
active
07049140
ABSTRACT:
A method of delivering an active agent to a target tissue, particularly neoplastic tissue, vascular anomaly or tumor tissue, in a vertebrate subject. The method includes the steps of exposing the target tissue to ionizing radiation; and administering a delivery vehicle to the vertebrate subject before, after, during, or combinations thereof, exposing the target tissue to the ionizing radiation. The delivery vehicle includes the active agent and delivers the agent to the target tissue. Representative delivery vehicles include platelets; leukocytes; proteins or peptides which bind activated platelets; antibodies which bind activated platelets; microspheres coated with proteins or peptides which bind activated platelets; liposomes conjugated to proteins or peptides, platelets, or leukocytes which bind activated platelets, or antibodies which bind activated platelets; and combinations thereof.
REFERENCES:
patent: 4515165 (1985-05-01), Carroll
patent: 4619823 (1986-10-01), Yokoyama et al.
patent: 4670386 (1987-06-01), Sugaar
patent: 5093104 (1992-03-01), Kaminsky
patent: 5292524 (1994-03-01), Male et al.
patent: 5328840 (1994-07-01), Coller
patent: 5334369 (1994-08-01), Halushka et al.
patent: 5382680 (1995-01-01), Abraham et al.
patent: 5516881 (1996-05-01), Lee et al.
patent: 5693627 (1997-12-01), Schieven
patent: 5759542 (1998-06-01), Gurewich
patent: 2003/0157025 (2003-08-01), Unger et al.
patent: 2621311 (1976-11-01), None
patent: 229718 (1987-01-01), None
patent: WO8605693 (1986-10-01), None
patent: WO9306835 (1993-04-01), None
patent: WO 93/14791 (1993-08-01), None
patent: WO9320229 (1993-10-01), None
patent: WO9533496 (1995-12-01), None
patent: WO 96/12956 (1996-05-01), None
patent: WO9625947 (1996-08-01), None
European Search Report for EP 00 93 5839.
Hirata et al., “Artificial Metastases and Decrease of Fibrinolysis in the Nude Mouse Lung After Hemithoracic Irradiation.” Clin. Expl. Metastasis, vol. 2 (No. 4), p. 311-319, (1984).
Hirata, “Fate of Intravenously Injected Human Tumor Cells in the Lung of Nude Mice Following Whole-Body X-Irradiation,” Invasion Metastasis, p. 61-70, (1985).
Stratton et al., “Imaging Arterial Thrombosis: Comparison of Technetium-99m-Labeled Monoclonal Antifibrin Antibodies and Indium-111-Platelets,” J. Nucl. Med., p. 1731-1737, (1994).
Weichselbaum et al., “Gene Therapy Targeted by Radiation Preferentially Radiosensitizes Tumor Cells,” Cancer Research, p. 4266-4269, (Aug. 15, 1994).
Song et al., “Combined Cytolytic Effect of X Irradiation and Cell-Mediated Immune Reactions on Tumor Cell in Vitro”,Radiology, vol. 111; 213-214, Apr. 1974.
Bender et al., “Enhancement of Monoclonal Antibody Efficacy: The Effect of External Beam Radiation”,Hybridoma, vol. 4 (No. 2); 129-134, Feb. 1995.
Jenkins Wilson Taylor & Hunt, P.A.
Ketter James
Vanderbilt University
LandOfFree
X-ray guided drug delivery does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with X-ray guided drug delivery, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and X-ray guided drug delivery will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3528292